Methods of treating chronic pain
The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-CGRP antibody.
1. A method for reducing incidence of or treating allodynia in an individual, comprising administering to the individual an effective amount of an anti-CGRP antagonist antibody, wherein the anti-CGRP antagonist antibody is a monoclonal antibody.
2. The method of claim 1 , wherein the anti-CGRP antagonist antibody is peripherally administered.
3. The method of claim 1 , wherein the anti-CGRP antagonist antibody is administered orally, sublingually, via inhalation, transdermally, subcutaneously, intravenously, intra-arterially, intra-articularly, peri-articularly, or intramuscularly.
4. The method of claim 3 , wherein the anti-CGRP antagonist antibody is administered subcutaneously or intravenously.
5. The method of claim 1 , wherein the anti-CGRP antagonist antibody acts peripherally on administration.
6. The method of claim 1 , wherein the anti-CGRP antagonist antibody blocks CGRP from binding to its receptor.
7. The method of claim 1 , wherein the anti-CGRP antagonist antibody blocks or decreases CGRP receptor activation.
8. The method of claim 1 , wherein the anti-CGRP antagonist antibody increases clearance of CGRP.
9. The method of claim 1 , wherein the anti-CGRP antagonist antibody inhibits CGRP synthesis, production or release.
10. The method of claim 1 , wherein the anti-CGRP antagonist antibody is a human antibody.
11. The method of claim 1 , wherein the anti-CGRP antagonist antibody is a humanized antibody.
12. The method of claim 1 , wherein the anti-CGRP antagonist antibody binds CGRP with a Kd of 50 nM or less as measured in an in vitro binding assay.
13. The method according to claim 1 , wherein the anti-CGRP antagonist antibody has a half-life in-vivo of at least 7 days.
14. The method of claim 1 , wherein the anti-CGRP antagonist antibody binds a C-terminal fragment having amino acids 25-37 of CGRP or a C-terminal epitope within amino acids 25-37 of CGRP.
15. The method of claim 1 , wherein the anti-CGRP antagonist antibody comprises: (a) CDR H1 as set forth in SEQ ID NO: 3 or 21; (b) CDR H2 as set forth in SEQ ID NO: 4 or SEQ ID NO: 22; (c) CDR H3 as set forth in SEQ ID NO: 5 or 23; (d) CDR L1 as set forth in SEQ ID NO: 6 or SEQ ID NO: 24; (e) CDR L2 as set forth in SEQ ID NO: 7 or SEQ ID NO: 25; and (f) CDR L3 as set forth in SEQ ID NO: 8 or 26.
16. The method of claim 1 , wherein the anti-CGRP antagonist antibody comprises a V H domain that comprises the amino acid sequence to SEQ ID NO: 1 and a V L domain that comprises the amino acid sequence to SEQ ID NO: 2.
17. The method of claim 1 , wherein the anti-CGRP antagonist antibody comprises a heavy chain produced by the expression vector with ATCC Accession No. PTA-6867.
18. The method of claim 1 , wherein the anti-CGRP antagonist antibody comprises a light chain produced by the expression vector with ATCC Accession No. PTA-6866.
19. The method of claim 1 , wherein the individual is a human.
20. The method of claim 1 , wherein the anti-CGRP antagonist antibody is formulated with a pharmaceutically acceptable excipient.